Global Search | Novartis

Sort by

Relevance

Newest first

Oldest first

Hide Filters

Showing 2969 results

Press release / Feb 25, 2026

Novartis to build new radioligand therapy site in Denton, Texas, delivering more next‑generation treatments to patients
Press release / Feb 23, 2026

Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)
Press release / Jul 17, 2026

Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN

Fabhalta slowed eGFR decline by 48% vs placebo over two years, demonstrating kidney function preservation1 Clinically meaningful improvements of protein in urine observed as early as two weeks,…
Press release / May 07, 2026

Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities

US Under Secretary of Commerce Jeffrey Kessler, Texas State Senator Brent Hagenbuch, Novartis leadership mark expansion of company’s coast-to-coast RLT manufacturing network – the largest in the…
Clinical Trials / Jul 10, 2026

Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).
Clinical Trials / May 20, 2026

Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA
Clinical Trials / Jul 13, 2026

Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
Clinical Trials / Jul 10, 2026

Modifying PEST for Psoriatic Arthritis Screening
Clinical Trials / Dec 30, 2025

LATAM LOWERS LDL-C
Clinical Trials / Jun 01, 2026

A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis